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Owing to the importance of major histocompatibility complex class Ia-restricted CD8+ T
cells for host survival following viral, bacterial, fungal, or parasitic infection, it has become
largely accepted that these cells should be considered in the design of a new generation
of vaccines. For the past 20 years, solid evidence has been provided that the heterologous
prime-boost regimen achieves the best results in terms of induction of long-lived protective
CD8+ T cells against a variety of experimental infections. Although this regimen has often
been used experimentally, as is the case for many vaccines, the mechanism behind the
efﬁcacy of this vaccination regimen is still largely unknown.Themain purpose of this review
is to examine the characteristics of the protective CD8+T cells generated by this vaccination
regimen. Part of its efﬁcacy certainly relies on the generation and maintenance of large
numbers of speciﬁc lymphocytes. Other speciﬁc characteristics may also be important,
and studies on this direction have only recently been initiated. So far, the characterization
of these protective, long-lived T cell populations suggests that there is a high frequency
of polyfunctional T cells; these cells cover a large breadth and display aT effector memory
(TEM) phenotype.TheseTEM cells are capable of proliferating after an infectious challenge
and are highly refractory to apoptosis due to a control of the expression of pro-apoptotic
receptors such as CD95. Also, they do not undergo signiﬁcant long-term immunological
erosion. Understanding the mechanisms that control the generation and maintenance of
the protective activity of these long-livedTEM cells will certainly provide important insights
into the physiology of CD8+ T cells and pave the way for the design of new or improved
vaccines.
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GENETIC VACCINATION USING THE HETEROLOGOUS
PRIME-BOOST REGIMEN
Genetic vaccination using naked DNA or recombinant viruses
is being pursued as an alternative to traditional vaccines. This
strategy could be particularly important in the case of intracellu-
lar pathogens and neoplastic cells, where the effectiveness relies
heavily on the capacity of the vaccine to elicit speciﬁc immune
responses mediated by cytotoxic CD8+ T cells (reviewed in Rice
et al., 2008; Lasaro and Ertl, 2009 Bassett et al., 2011; Gómez et al.,
2011; Mudd and Watkins, 2011; Saade and Petrovsky, 2012).
Whereas the use of single-vector delivery for priming and
boosting is usually the initial option, one of the most proliﬁc
areas of genetic vaccine development is the strategy known as
the heterologous prime-boost regimen. This strategy uses two
different vectors, each carrying a gene that encodes the same
antigenic protein for priming and boosting immunizations. The
utility and importance of this strategy was ﬁrst proposed in
the early 1990s using a combination of recombinant viruses
(inﬂuenza and vaccinia) to induce protective immunity against
malaria (Li et al., 1993; Rodrigues et al., 1994). Subsequently, this
approach was extended and simpliﬁed by incorporating naked
DNA for priming followed by a booster injection of a recombinant
poxviral vector (i.e., modiﬁed vaccinia Ankara, MVA); this was
also used to generate sterile protective immunity against rodent
malaria (Schneider et al., 1998; Sedegah et al., 1998). Collectively,
these studies demonstrated that the heterologous prime-boost
regimen generated signiﬁcantly higher immune responses and
proved more effective than the use of any of these genetic vec-
tors individually. The initial use of rodent malaria parasites
as a model system may have delayed the development of the
ﬁeld, because malaria is not a conventional model system for
developing antiviral or antibacterial vaccines. Nevertheless, this
fortuitous fact established the important concept that the difﬁ-
culty in generating immunity to malaria, and perhaps to other
intracellular parasites, in many ways recapitulates the struggles
encountered to elicit protective immunity against viruses and
bacteria that case chronic infections such as HIV and tuber-
culosis (TB).
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In subsequent years, the heterologous prime-boost vaccina-
tion regimen was adopted worldwide as a powerful means to elicit
strong type 1 effector CD8+ T cell-mediated immune responses
(Tc1) against viral, parasitic, and neoplastic antigens in rodents
and non-human primates (NHP; Irvine et al., 1997; Amara et al.,
2001; McShane et al., 2001; Zavala et al., 2001; Moore and Hill,
2004; Ellenberger et al., 2006; Gilbert et al., 2006; Aidoo et al., 2007;
Nigam et al., 2007; Martinon et al., 2008; Sadagopal et al., 2008).
Based on pre-clinical studies, a number of human clinical trials
have also been initiated. However, to our knowledge, heterolo-
gous prime-boost regimens using plasmid DNA and recombinant
poxviruses have not yet provided meaningful protective immunity
in humans (McConkey et al., 2003; Moorthy et al., 2004; Keat-
ing et al., 2005; Vuola et al., 2005; Cebere et al., 2006; Dunachie
et al., 2006; Goonetilleke et al., 2006). The precise reason for such
failures is not yet clear. It may be due to the target antigens cho-
sen or to the possibility that the combination of vectors may
elicit a type of effector CD8+ T cells in humans that are not
functionally and/or phenotypically related to mice, as discussed
below.
A number of possible vector combinations that signiﬁcantly
improved cell-mediated immunity, particularly the generation of
speciﬁc CD8+ T cells, have been described in parallel. Among
them, heterologous prime-boost vaccination using naked plasmid
DNA for priming followed by a booster injection of recom-
binant replication-deﬁcient human adenovirus 5 (AdHu5) has
recently received signiﬁcant attention. This strategy has proved
successful in some relevant experimental models such as simian
immunodeﬁciency virus (SIV),malaria,Marburg, and Ebola virus
infection, and Chagas disease (American trypanosomiasis), pro-
viding a considerable degree of protective immunity (Gilbert et al.,
2002; Casimiro et al., 2003, 2005; Santra et al., 2005; Acierno et al.,
2006; Letvin et al., 2006; Mattapallil et al., 2006; Sun et al., 2006;
Wilson et al., 2006; de Alencar et al., 2009; Geisbert et al., 2010;
Hensley et al., 2010; Martins et al., 2010; Dominguez et al., 2011;
Rigato et al., 2011). These relative successes obtained inpre-clinical
experimental models fueled human phase I trials (Freel et al.,
2010; Jaoko et al., 2010; Koup et al., 2010; Schooley et al., 2010;
Churchyard et al., 2011; De Rosa et al., 2011).
Very recently, improved vector combinations have yielded
results (measured in terms of protective immunity) that are
slightly better than the results obtained by using plasmid DNA
followedby replication-deﬁcientAdHu5 viruses. These new strate-
gies include (i) prime with plasmid DNA in the presence of
cytokine genes such as IL-12 orGM-CSF (Lai et al., 2011;Winstone
et al., 2011), (ii) genes encoding multimeric proteins (Lakhashe
et al., 2011), (iii) boost of adenovirus-immunized animals with
an optimized plasmid DNA (Hutnick et al., 2012), (iv) prime with
rhesus cytomegalovirus (Hansen et al., 2011), and (v) prime with a
different heterologous strain of adenovirus (Barouch et al., 2012).
The precise reason for the superior performance of the heterol-
ogous prime-boost vaccination compared to the sequential use of
the same vector is still a matter of controversy. Some evidence
indicates the possibility that the intense immunity to epitopes
present on the priming vector prevents the boosting effect. For
example, a recent study in humans shows that a second dose
of a recombinant AdHu5 does not provide signiﬁcant boosting.
In parallel, recombinant AdHu5 boosting of DNA-primed indi-
viduals resulted in signiﬁcantly higher immune responses (De
Rosa et al., 2011). The anti-vector immunity can be either anti-
bodymediated or independent (Cockburn et al., 2008; Schirmbeck
et al., 2008; Frahm et al., 2012). Haut et al. (2011) found that in B
cell-deﬁcient mice transgene-speciﬁc CD8+ T cell responses were
signiﬁcantly higher in systemic compartments. In contrast, recent
studies in humans showed that neutralizing antibodies titers to
AdHu5 did not correlate with the magnitude of speciﬁc CD8+ T
cell of priming after immunization with a recombinant AdHu5.
In these experiments, the frequency of speciﬁc CD4+ T cells nega-
tively correlatedwith the intensity of speciﬁcCD8+ Tcells priming
(Frahm et al., 2012).
In spite of the clear evidences that pre-existing immunity may
interfere with the use of viral vectors, still, the heterologous prime-
boost regimen of immunization is described as a possible solution
to this problem. This can be achieved by strong priming with
cytokine genes (for example, see Barouch et al., 2003).
Independent of the reasons why the heterologous prime-boost
vaccination regimen is superior to the sequential use of the same
vector, themain purpose of this review is to examine the character-
istics of the protective CD8+ T cells generated by this vaccination
regimen.
CHARACTERISTICS OF PROTECTIVE CD8+ T CELLS
ELICITED AFTER HETEROLOGOUS PRIME-BOOST
VACCINATION
HIGH FREQUENCIES OF SPECIFIC CD8+ T CELLS
Onehallmarkof theheterologous prime-boost regimen is the elici-
tationof a higher frequency of epitope-speciﬁcCD8+ Tcells across
multiple models. This high number of effector T cells was initially
estimated by the presence of epitope-speciﬁc IFN-γ-producing
cells using the ex vivo ELISPOT assay (Murata et al., 1996; Schnei-
der et al., 1998; Sedegah et al., 1998; Bruña-Romero et al., 2001).
Subsequently, the hypothesis was further validated by intracellu-
lar staining for IFN-γ (Pinto et al., 2003) and tetramer staining
of epitope-speciﬁc CD8+ T cells (Tao et al., 2005). More recently,
intracellular staining for TNF, IL-2, MIP1-β, T cell surface mobi-
lization of CD107a, and in vivo cytotoxicity provided extended
evidence (for examples, see Masopust et al., 2006; Mattapallil et al.,
2006; Cox et al., 2008; de Alencar et al., 2009; Freel et al., 2010;
Reyes-Sandoval et al., 2010; Rigato et al., 2011).
Because most studies are performed with T cells collected from
the spleen or peripheral blood lymphocytes (PBL) of mice orNHP,
respectively, it is not clear whether these results reﬂect an over-
all increase in every tissue. The presence of a large number of
epitope-speciﬁc T cells in several tissues has been documented
in the case of mouse lung, liver, intraepithelial lymphocytes, and
PBL (Masopust et al., 2006; Reyes-Sandoval et al., 2011); however,
because parallel comparison was not performed with animals that
were immunized with a single vector, it is not clear whether these
levels were particularly higher than the other vaccination proto-
cols. Conversely, the frequency of epitope-speciﬁc CD8+ T cells
seems to decrease in mouse lymph nodes (Masopust et al., 2006).
This may be due to the lack of CD62L expression on the surface
of these activated T cells, as discussed below. In addition, the
pattern of circulation and recirculation of these lymphocytes has
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been poorly explored. A single study, however, demonstrated that,
after a recombinant plasmid DNA prime-AdHu5 boost, CD8+
T cells need to recirculate in order to exert protective immunity
against an infectious challenge with the protozoan parasite Try-
panosoma cruzi. In these vaccinated mice, treatment with the
drug FTY720 signiﬁcantly reduced the efﬁcacy of the protec-
tive immunity by interfering speciﬁcally with signaling through
sphingosine-1-phosphate receptor-1, thereby inhibiting the egress
of T cells from the lymph nodes (Dominguez et al., 2012). This
observation is important because immunity to certainpathogens is
not dependent on the recirculation of T lymphocytes (Pinschewer
et al., 2000; Kursar et al., 2008; Jiang et al., 2012).
The importance of recirculation is likely dependent on factors
such as (i) the host, (ii) the vectors used for prime and/or boost,
and (iii) the route of administration of each vector (for exam-
ples, see Mattapallil et al., 2006; Kaufman et al., 2010). These are
important characteristics that will certainly inﬂuence the protec-
tive immunity, as pathogens can cause either tissue-speciﬁc or
systemic infections.
The T cell protective immunity elicited by heterologous prime-
boost regimen is not only signiﬁcantly higher than the immunity
elicited by the traditional vaccine regimen but is also longer-lived.
Several experimental models have shown that the immunity lasts
for signiﬁcant periods of time (Amara et al., 2001; Bruña-Romero
et al., 2001; de Alencar et al., 2009; Reyes-Sandoval et al., 2010;
Rigato et al., 2011).
POLYFUNCTIONALITY OF SPECIFIC CD8+ T CELLS
Based on the assays described above, it became clear that the
speciﬁcCD8+ T cells elicited by the heterologous prime-boost reg-
imen could exert different immunological functions, as measured
by ex vivo or in vivo assays. Conﬁrmation of the polyfunctionality
of these cells was made possible through FACS analyses coupling
intracellular cytokine staining and cell surface mobilization of the
degranulation marker CD107a.
Accordingly, a number of studies conﬁrmed that distinct het-
erologous prime-boost regimens elicited polyfunctional CD8+
T cells as deﬁned by the cells’ capability to exert two or more
functions at the same time. The most frequent example of this
across different models is speciﬁc CD8+ T cells producing IFN-
γ and TNF simultaneously. High frequencies of polyfunctional
speciﬁc CD8+ T cells were described in (i) mice (Masopust et al.,
2006; Duke et al., 2007; de Alencar et al., 2009; Elvang et al., 2009;
Reyes-Sandoval et al., 2010; Rigato et al., 2011; Rodríguez et al.,
2012; Vijayan et al., 2012), (ii) NHP (Mattapallil et al., 2006; Sun
et al., 2006; Cox et al., 2008; Liu et al., 2008; Magalhaes et al.,
2008; Cayabyab et al., 2009; Wilks et al., 2010; Hutnick et al.,
2012), and (iii) humans (Beveridge et al., 2007; Harari et al., 2008;
Winstone et al., 2009; Freel et al., 2010; Jaoko et al., 2010; Koup
et al., 2010; Schooley et al., 2010; Churchyard et al., 2011; De Rosa
et al., 2011).
It is noteworthy that although these T cells have a high fre-
quency of polyfunctionality, their ability to mediate multiple
immunological functions has never been clearly linked to their
protective capacity. It is possible that this characteristic aids in
but is not critical for their effector functions, depending on the
mechanism necessary for pathogen elimination. In a single study
performed using genetically deﬁcientmice, in the absence of either
IFN-γ or perforin, heterologous prime-boost vaccination failed to
mediate protective immunity against infection with the intracel-
lular parasite T. cruzi. In the case of perforin-deﬁcient mice, the
lack of protective immunity was associated mainly with a sig-
niﬁcant decrease in the induction of polyfunctional T cells (de
Alencar et al., 2009). A second study correlated the presence of
higher frequencies of polyfunctional T cells to protective immu-
nity against liver stages of malaria parasite (Reyes-Sandoval et al.,
2010). Although these studies may suggest a role for polyfunc-
tional T cells during protective immunity, it is still too early to
conclude that they are critical for the protective immunity exerted
by CD8+ T cells elicited following the heterologous prime-boost
vaccination regimen.
BREADTH OF SPECIFIC CD8+ T CELLS
T cell immune responses are often restricted to a few immun-
odominant epitopes, a phenomenon termed immunodominance
(Akram and Inman, 2012). The precise reason for such a restric-
tion is not clear; however, it may have evolved to maximize the
immune response, while at the same time reducing the risk of
autoimmunity. For the purpose of vaccine development, having
only a narrow number of recognized epitopes may be dangerous,
as the pathogens will rapidly select for escape mutants to avoid
effector immune responses (reviewed in Streeck and Nixon, 2010;
Chopera et al., 2011).
Although it has been possible to increase the frequency of T
cells speciﬁc for immunodominant epitopes, it is still a challenge
to broaden the vaccine-induced CD8+ T cell response to a number
of subdominant T cell epitopes. There is evidence that heterol-
ogous rAdHu5 boosting improved not only the magnitude but
also the breadth of speciﬁc CD8+ cells (Liu et al., 2008). How-
ever, the impact of this response on protective immunity is not
clear. Two recent studies indicated that immunity to subdominant
epitopes might participate in vaccine-induced protective immu-
nity following a DNA prime-AdHu5 boost vaccination regimen.
The ﬁrst study provided a correlation between the breadth of
the immune response and the protective immunity observed in
individual rhesus monkeys vaccinated with SIV genes (Martins
et al., 2010). A second study formally demonstrated that het-
erologous prime-boost vaccination with plasmid DNA followed
by recombinant AdHu5 elicited strong immune response to two
subdominant epitopes that were not recognized during infection
(Dominguez et al., 2011). Based on these observations, mutant
genes were generated inwhich the dominant epitopewas removed.
Heterologous prime-boost vaccination with these mutant genes-
induced CD8+ T cell immune responses only to the subdominant
epitopes. Most importantly, strong CD8+ T cell-mediated immu-
nity was still observed (Dominguez et al., 2011). These results
unequivocally demonstrate the importance of immunity to the
subdominant epitopes and the ability of the heterologous prime-
boost to elicit them. Nevertheless, other groups still have difﬁculty
improving the immune response to subdominant epitopes fol-
lowing heterologous prime-boost vaccination of NHP (Vojnov
et al., 2011). Therefore, new strategies to improve the breadth of
the immune response might be developed in order to potentiate
vaccine formulation.
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TEM PHENOTYPE OF SPECIFIC LONG-LIVED CD8+ T CELLS
The current immunological paradigmdivides antigen-experienced
CD8+ T cells into three main types: (i) T effector (TE), (ii)
T effector memory (TEM), and (iii) T central memory (TCM).
These populations of T cells can be distinguished by the pres-
ence of activation markers, as well as by differences observed
in their localization and recirculation patterns and their ability
to proliferate and present certain effector functions/molecules
(Angelosanto and Wherry, 2010; Cui and Kaech, 2010; Ahmed
and Akondy, 2011; Sheridan and Lefrançois, 2011). More recently,
other subpopulations of CD8+ T cells have also been described
(Wakim et al., 2010; Sheridan and Lefrançois, 2011; Jiang et al.,
2012). The concept of TE/TEM/TCM was primarily established
by experimental infections with self-curing pathogens. In these
cases, TE are short-lived effector cells (CD44High CD11aHigh
CD62LLow CD127Low KLRG1High); TCM are long-lived memory
cells (CD44High CD11aHigh CD62LHigh CD127High KLRG1High);
and TEM are transitional cells that exist for a short period of
time and have distinct surface marker expression (CD44High
CD11aHigh CD62LLow CD127High KLRG1High). However, even
by using models of self-curing infections, the existence of
other memory T cell subpopulations that might be more rele-
vant for long-term T cell immunity have been proposed (Hikono
et al., 2007).
In addition, very recently, considerable interest has been placed
on tissue-resident memory T (TRM) cells. These cells are potent
long-lived effector cells present in a variety of peripheral tissues
including the skin and sensory ganglia, gut, brain, lung, etc.
(Wakim et al., 2008; Gebhardt et al., 2009; Masopust et al., 2010;
Purwar et al., 2011). They mediate protective immunity against
brain infection with vesicular stomatitis virus or skin infection
with vaccinia or herpes simplex virus (Wakim et al., 2010; Jiang
et al., 2012; Mackay et al., 2012). Their phenotype is CD44High,
CD62LLow, CD103High, CD69High, CD127Low, and PD-1Low. The
relationship of TRM cells with TEM or TCM is yet to be determin-
ed. Some authors propose that these cells constitute an independ-
ent lineage primed within the tissue (Wakim et al., 2010, 2012).
Very recently, the development of a methodology to per-
form transcriptional proﬁling at the single cell level has detected
further differentiation proﬁles among TEM and TCM. The anal-
ysis of speciﬁc splenic CD8+ T cells from mice immunized
with distinct vaccination protocols yields signiﬁcant differences
among these subpopulations (Flatz et al., 2011). For example,
while 74% of the speciﬁc TEM elicited by the heterologous
DNA prime-recombinant AdHu5 boost vaccination were Klrk1−
Klrg1− Ccr5−, only 20% of the cells generated by HuAd5-prime-
recombinant LCMV boost had a similar phenotype (Flatz et al.,
2011). This type of analysis further highlights the heterogeneity
still being uncovered within these memory cells.
It has been observed on multiple occasions that after heterolo-
gous prime-boost vaccination, the boosting immunization drives
not only an expansion of the T cells but also a different phenotype
in the long-lived memory T cells. Different doses of the vaccine
also caused a signiﬁcant increase in the frequency of speciﬁc CD8+
T cells with a TEM phenotype (CD44High CD11aHigh CD62LLow
CD127High KLRG1High; Masopust et al., 2006). TEM cells were
described initially as highly protective against certain viral and
bacterial infections (Bachmann et al., 2005a,b; Huster et al., 2006).
Likewise, protective immunity afforded by the different heterolo-
gous prime-boost vaccination protocols has been associated with
the presence of this type of T cell (Hansen et al., 2011; Reyes-
Sandoval et al., 2011; Rigato et al., 2011; Xiao et al., 2011; Barouch
et al., 2012; Yamamoto et al., 2012).
Based on the relatively poor knowledge of the surface activa-
tion markers present on long-lived speciﬁc TEM CD8+ T cells,
we performed a detailed analysis of the different T cells markers
following intramuscular DNA prime-adenovirus boost immu-
nization. We identiﬁed transgenic epitope-speciﬁc T cells in the
spleen of immunized mice 14 or 98 days after the boost vaccina-
tion. Figure 1 summarizes the surface marker phenotype of these
epitope-speciﬁc T cells compared to the phenotype of the naïve
cells.
PROLIFERATIVE CAPACITY OF SPECIFIC CD8+ T CELLS
Theproliferative capacity of speciﬁcT cells elicitedbyheterologous
prime-boost vaccination has not been thoroughly studied to date.
In general, after resolution of experimental self-curing infections,
the frequency of total CD8+ T cells declines to less than 10% of the
maximal number of speciﬁc T cells observed during the peak of
the immune response; this is known as the contraction phase. The
decrease in the number of speciﬁc T cells occurs mainly among the
short-lived effector cells (Angelosanto and Wherry, 2010; Cui and
Kaech, 2010; Ahmed and Akondy, 2011; Sheridan and Lefrançois,
FIGURE 1 | Phenotype of specific CD8+ T cells elicited by heterologous
prime-boost vaccination using recombinant plasmid DNA andAdHu5.
Prime-boost regimen was performed as detailed described by Rigato et al.
(2011). Mice were primed i.m. with plasmid DNA (100 μg) and boosted 21
days later with AdHu5 (2 × 108) both expressing the gene encoding the
amastigote surface protein-2 ofT. cruzi. Expression of distinct
adhesion/activation receptors on the surface of splenic CD8+ speciﬁc T
cells is shown at day 14 or day 98 after the boost immunization.
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2011). However, this does not seem to be the case for the TE
cells elicited by the heterologous prime-boost vaccination regimen
(Jameson and Masopust, 2009). In this case, the cells expand and
aremaintained at a high frequency in the spleen for a longperiodof
time (Masopust et al., 2006; Vezys et al., 2009; Rigato et al., 2011).
This is a somewhat unexpected ﬁnding and might be of great
relevance for the success of this vaccination protocol. Because this
expansion andmaintenance contrasts with the retraction observed
after self-curing infections, it opens a number of questions that
should be studied in depth: (i) How can cells expand out of control
to reach frequencies higher than the primary immune response?
(ii) How do T cells avoid the apoptotic process observed for the
short-lived effector cells during the contraction phase? (iii) How
are T cells maintained for these long periods? These questions
are keys to understanding the physiology of CD8+ T cells and
developing better T cell vaccines.
After an infectious challenge, speciﬁc T cells proliferate. How-
ever, it is still unknown whether this proliferative response occurs
among the antigen-primed TE(M) cells, rare TCM or naïve T
cells. To address this question, it is now possible to use the gzm-
BCreERT2/ROSA26EYFP transgenic mouse line (Bannard et al.,
2009). Speciﬁc TE CD8+ T lymphocytes can be indelibly labeled
with enhanced yellow ﬂuorescent protein (EYFP). Following an
infectious challenge, it will be possible to follow the expansion of
EYFP-labeled TE cells. This result will conﬁrm or not whether
the cells that expand after the infectious challenge are indeed
mainly antigen-experienced TE. Also, by the adoptive transference
of green-ﬂuorescent naïve speciﬁc T cells prior to the infectious
challenge it will be possible to determine whether these cells pro-
liferate or not together with the speciﬁc TE cells. Whether this is
true for all different protocols of heterologous prime-boost vac-
cination strategies is still unknown and might be relevant for the
development of vaccines to be used in individuals primed with
conventional vaccines such as Bacillus Calmette–Guérin (BCG;
Hoft et al., 2012).
REFRACTORINESS TO APOPTOSIS OF SPECIFIC CD8+ T CELLS
As mentioned above, after an intense immune response and
pathogen elimination, the number of speciﬁc CD8+ T cell is
drastically reduced during a period called the contraction phase.
In that period, TE or short-lived effector cells are eliminated by
mechanisms that involve apoptosismediatedbyBCL-2-interacting
mediator of cell death (Bim) andCD95 (also known as FAS;Green,
2008; Hughes et al., 2008; Weant et al., 2008; Bouillet and O’Reilly,
2009). We observed that following prime-boost immunization
with recombinant plasmid DNA and AdHu5, TEM cells do not
upregulate surface CD95 expression and are refractory to anti-
CD95-induced apoptosis in vitro (Rigato et al., 2011). Because
CD95 is an important initiator of the intrinsic pathway of apopto-
sis in T lymphocytes, low levels of expression may protect T cells
from apoptotic death.
Decreased levels of expression or resistance to activation of
other receptors that control T cell death, such as TNF receptor
and TRAIL, might also play a role during the survival of speciﬁc
TEM cells. In contrast, increased expression of other receptors
may act to protect these speciﬁc T cells. Recently, expression of
PDL-1 (B7-H1) on antigen-activated CD8+ T cells made these
cells more resistant to Ca2+-dependent and Fas ligand-dependent
killing by cytotoxic T lymphocytes (Pulko et al., 2011). However,
more details are necessary to understand the expression levels of
many of these molecules controlling T cell survival.
It is plausible that Bim is poorly activated, or not activated
at all, on these cells. Because Bim is activated in response to the
lack of certain external stimuli, these activation signals might be
maintained for long-term. One suchmechanism is antigen presen-
tation by dendritic cells. Using a replication-deﬁcient adenoviral
vector, Tatsis et al. (2007) demonstrated that the transgene product
remains available for antigen presentation for as long as 16 weeks
after a single immunizing dose. The importance of continuous
transgene expression in the maintenance of the speciﬁc CD8+ T
cells after AdHu5 vaccination was also demonstrated by a causal
relationship between both using an inducible system to turn off
the transgene expression (Finn et al., 2009). Bassett et al. (2011)
showed that both hematopoietic and non-hematopoietic antigen-
presenting cells are necessary for the maintenance of CD8+ T cells
following immunization with recombinant adenovirus. However,
it is not clear whether antigen persistence is also observed with
other vectors.
We tested whether the IFN-γ or IL12/IL23 signaling pathways
might be important for maintaining these long-lived CD8+ TEM
cells. The absence of either pathway individually made little dif-
ference in the generation of speciﬁc CD8+ T cells. The absence
of the IL12/IL23 pathway, but not the IFN-γ pathway, was impor-
tant for the long-term survival of these cells (Rigato et al., 2011).
Further details regarding the relevance of these signaling pathways
in maintaining a high frequency of CD8+ T cells are unknown.
In addition, little is known about the impact of the lack of the
IL12/IL23 pathway in the maintenance of speciﬁc CD8+ T cells
after other heterologous prime-boost vaccination regimens. We
consider this area of critical importance in understanding how T
cells can be maintained at high frequencies for long periods of
time. A possible explanation that remains to be tested is whether
the lack of contraction could be due to the fact that many spe-
ciﬁc long-lived CD8+ T cells express low levels of the chemokine
receptors CXCR3 and CCR5 (Flatz et al., 2011). This possibility is
supported by recent observations that genetically deﬁcient CD8+
T cells that do not express both these receptors were refractory
to contraction and accumulated in higher numbers in the spleen
(Kohlmeier et al., 2011).
Recently, we described a new and potentially very important
aspect of CD8+ TE cells. After recombinant AdHu5 vaccina-
tion, CD8+ TE cells do not undergo apoptosis, as well as prevent
the development of a pro-apoptotic phenotype that occurs dur-
ing experimental infection with the protozoan parasite T. cruzi.
This phenomenon was observed when the administration of the
recombinant AdHu5 vaccine was provided before (as part of a
prime-boost regimen or alone) or at the time of the infectious
challenge. AdHu5 treatment modulated speciﬁcally the CD8+ TE
cells to express lower levels of CD95 (FAS) and become resistant to
CD95-induced apoptosis. The determination of the distinct adhe-
sion/activation receptors on the surface of the CD8+-speciﬁc T
cells elicited by either infection or recombinantAdHu5 immuniza-
tion showed very limited differences that were almost exclusively
conﬁned to the apoptotic receptor CD95 (Figure 2).
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FIGURE 2 | Expression of distinct adhesion/activation receptors on the
surface of specific CD8+ T cells elicited by eitherT. cruzi infection or
recombinant AdHu5 immunization (Vasconcelos et al., 2012). Mice
were infected s.c. withT. cruzi (150 blood stream trypomastigotes) or
immunized i.m. with AdHu5 (2 × 108 pfu) expressing the gene encoding
the amastigote surface protein-2 ofT. cruzi 19 days earlier.
Despite the above results, we have not ruled out that other
pro-apoptotic signaling pathways might also be altered. In these
immunized and challenged mice, the CD8+ T cell population
expanded largely and protected mice against an otherwise lethal
infection (Vasconcelos et al., 2012). An important mechanism that
controls the expression of CD95 on the surface of speciﬁc CD8+
T cells has just been described during development of immune
responses to viral infections. TCR activation led to an increase of
the RIG-I-like receptor LGP2 expression which down-regulated
CD95 expression. In KO mice, the absence of this molecule signif-
icantly increased the apoptosis reducing the effectiveness of the
immune response and resistance to the viral infection (Suthar
et al., 2012). We consider this a promising area of study because it
suggests that perhaps the control of T cell survival might be the
key element for the development of new or improved vaccines.
The proposed pathway of speciﬁc CD8+ T cell activation follow-
ing prime-boost vaccination and infection is shown in Figure 3
(based on Vasconcelos et al., 2012).
REDUCED IMMUNOLOGICAL EROSION OF SPECIFIC CD8+ T CELLS
Memory CD8+ T cells are not a stable pool; subsequent infec-
tions may cause attrition and erosion of the memory T cell
pool (Selin et al., 1996, 1999; Dudani et al., 2008; Huster et al.,
2009; Schmidt and Harty, 2011). However, different heterologous
prime-boost regimens generated a pool of CD8+ T cells that
was not eroded by subsequent viral infections (Vezys et al., 2009;
Rigato et al., 2011). After a vaccination regimen consisting of
recombinant plasmid DNA prime-AdHu5 boost, we observed that
viral infections had limited impact on the number or quality
of the TEM cells as measured by different functional immuno-
logical assays. Most importantly, protective immunity mediated
by these CD8+ TEM cells was not altered in these mice (Rigato
et al., 2011).
In contrast, using a different prime-boost vaccination protocol
consisting of dendritic cells coated with circumsporozoite protein
peptide and a booster immunization with recombinant actA–
inlB-deﬁcient Listeria monocytogenes expressing the same epitope
elicited an immune response that could be eroded by multiple
subsequent infections (Schmidt and Harty, 2011). The discrepant
results highlight the importance of determining the characteristic
of each TEM elicited by the distinct regimen of vaccination, as
suggested earlier (Flatz et al., 2011).
The resistance to immunological erosion is one more inter-
esting characteristic of these long-lived TEM cells that has been
poorly explored and may have an important impact in the
development of efﬁcient vaccines. As mentioned above, this
high-resistance immunological erosion can be linked to the dif-
ferential expression of surface molecules (death receptors such as
CD95/FAS) or apoptosis mediators (such as Bim).
UNKNOWN FATE OF THE SPECIFIC CD8+ TEM CELLS
Although some studies described that theses TEM can be long-
lived in some mouse models, it is not clear what will be the fate
of these cells on extended periods of time. Will they become
TCM by upregulating CD62L? Will they simple die? Can they
be boosted? Perhaps these questions can be addressed by using
the gzmBCreERT2/ROSA26EYFP transgenicmouse line (Bannard
et al., 2009). Labeling speciﬁc TE CD8+ T lymphocytes will allow
us to follow theses cells for longer periods of time.
Also, their long-term fate in NHP or humans is even more
important for the purpose of development of practical vaccines.
Due to the obvious constrains, few studies so far have addressed
this issue.
CONCLUDING REMARKS AND PERSPECTIVES
Genetic vaccination using heterologous prime-boost regimen pro-
tocols has the potential to serve as the basis for the development of
new vaccines against many pathogens. In spite of the progress over
the past 20 years, much work is required to improve the relevance
of vaccine research, considering that human immune response is
still at least one order of magnitude lower than that observed in
mouse or even NHP models.
Several areas can be pursued for this matter. So far, protec-
tive immunity is clearly associated with the presence of a high
number of long-lived speciﬁc polyfunctional TEM cells. Nev-
ertheless, several points should be considered. First, TEM may
vary from one protocol to the other. It is also important to
improve the number of speciﬁc TCM cells, for example, by using
pharmacological modulators (Li et al., 2012; Takai et al., 2012).
However, it will be a challenge to increase the number of TCMcells
without reducing the number of TEM cells. Fine tuning the TEM
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FIGURE 3 |The proposed pathway of activation of specific CD8+
T cells following prime-boost vaccination and infection (based on
Vasconcelos et al., 2012). Prime-boost regimen was performed as
detailed described by Rigato et al. (2011). Mice were primed i.m. with
plasmid DNA (100 μg) and boosted 21 days later with AdHu5 (2 × 108)
both expressing the gene encoding the amastigote surface protein-2
ofT. cruzi. Mice were infected s.c. withT. cruzi (150 blood stream
trypomastigotes).
subpopulations and increasing the number of TCM cells could
further improve and prolong protective immunity beyond the lev-
els currently achieved. Furthermore, new strategies to broaden the
epitopes recognized by protective T cells would also improve both
the quantity and the quality of the immune response. Finally, the
circulation of these cells should be further studied for the pur-
pose of personalizing the vaccination regimen for different types
of infections, considering that the site of entry of each pathogen
will vary, as will the localization of the T cells at the time of the
infection.
In summary, the study of the control of memory T cell
generation, maintenance, quality, and recirculation after dis-
tinct heterologous prime-boost vaccination regimens will pro-
vide important clues regarding the physiology of lymphocytes
and the immune system, with potential applications in public
health.
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